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Background: We recently developed two Bayesian networks, referred to as the Bayesian-Estimated Tools for
Survival (BETS) models, capable of estimating the likelihood of survival at 3 and 12 months following surgery for
patients with operable skeletal metastases (BETS-3 and BETS-12, respectively). In this study, we attempted to
externally validate the BETS-3 and BETS-12 models using an independent, international dataset.
Methods: Data were collected from the Scandinavian Skeletal Metastasis Registry for patients with extremity
skeletal metastases surgically treated at eight major Scandinavian referral centers between 1999 and 2009. These
data were applied to the BETS-3 and BETS-12 models, which generated a probability of survival at 3 and 12 months
for each patient. Model robustness was assessed using the area under the receiver-operating characteristic curve
(AUC). An analysis of incorrect estimations was also performed.
Results: Our dataset contained 815 records with adequate follow-up information to establish survival at 12 months.
All records were missing data including the surgeon’s estimate of survival, which was previously shown to be a
first-degree associate of survival in both models. The AUCs for the BETS-3 and BETS-12 models were 0.79 and 0.76,
respectively. Incorrect estimations by both models were more commonly optimistic than pessimistic.
Conclusions: The BETS-3 and BETS-12 models were successfully validated using an independent dataset containing
missing data. These models are the first validated tools for accurately estimating postoperative survival in patients
with operable skeletal metastases of the extremities and can provide the surgeon with valuable information to
support clinical decisions in this patient population.
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Accurate, personalized survival estimates are important
for patients with metastatic disease, partly because they
can help guide surgical decision-making [1,2]. Import-
antly, survival estimates can help identify not only which
patients may benefit from surgery but also which surgi-
cal procedure may be most appropriate. Both features
are critical in the effort to avoid under- or overtreatment
of the disease. Prognostic variables are generally* Correspondence: jaforsberg@me.com
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reproduction in any medium, provided the orconsidered favorable or unfavorable and include infor-
mation based on oncologic diagnosis [3,4], extent of dis-
ease [5], the patient’s performance status [6], and basic
laboratory assessments [7].
To better understand the relationships and relative im-
portance of prognostic variables in patients with skeletal
metastases, we previously analyzed readily available clin-
ical data on a particular subset of these patients. Using a
fully machine-learned algorithm, we developed two
Bayesian classifiers to estimate the likelihood of survival
at 3 and 12 months following the surgical treatment of
skeletal metastases [4]. These clinical decision support
models are referred to as the Bayesian Estimated Tools
for Survival—the BETS-3 and BETS-12 models (Figures 1al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





















Figure 1 BETS-3 model structure. As shown, there are 5 first-degree associates of 3-month survival: surgeon’s estimate of survival, preoperative
hemoglobin concentration, preoperative absolute lymphocyte count, ECOG performance status, and presence of a complete pathologic fracture.
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were chosen because they are widely considered useful
for orthopaedic surgical decision making [8-10]. Specif-
ically, when surgical stabilization is deemed necessary,
shorter life expectancies are thought to warrant less-
invasive stabilization procedures, such as intramedullary
or plate fixation, that do not require prolonged rehabili-
tation periods. Accordingly, longer life expectancies may
warrant more durable reconstruction procedures, using
endoprostheses, which are associated with significant op-
erative morbidity and longer rehabilitation times [8-10].
We developed two models because Bayesian classifiers are
not well suited to provide discrete estimates in time, but
rather probabilities of a particular outcome (in this case,
survival >3 or >12 months).
First-degree associates of survival (those most closely
associated with the outcome) differed between the 2 models
[4]. In the BETS-3 model (Figure 1), the senior surgeon’s
estimate of survival, preoperative hemoglobin concentra-
tion, absolute lymphocyte count, presence of a completed
pathologic fracture, and Eastern Cooperative Oncology
Group (ECOG) performance status were found to be first-
degree associates. In the BETS-12 model (Figure 2), the
surgeon’s estimate of survival, preoperative hemoglobin
concentration, number of bone metastases, and oncologic
diagnosis group were shown to be first-degree associates.
Both models were internally validated using 10-fold cross-
validation methods.Figure 2 BETS-12 model structure. As shown, there are four first-degree
preoperative hemoglobin concentration, number of bone metastases, andThe purpose of this study was to externally validate
the BETS-3 and BETS-12 models using an independent,
international skeletal metastasis registry containing the
records of patients with operatively treated skeletal me-
tastases. Three- and 12-month rates of survival were
again used as the primary endpoints. Because Bayesian
classification can effectively account for data uncertainty,
it can be used in the setting of missing data, as com-
monly occurs in large, population-based registries such
as the one chosen for this study.
Methods
Data collection
The Scandinavian Sarcoma Group established the Scandi-
navian Skeletal Metastasis Registry (SSMR) in 1999 in an
effort to improve the treatment of patients with skeletal
metastases. The SSMR contains the records of patients
with skeletal extremity metastases who were surgically
treated at one of eight major Scandinavian referral centers
between 1999 and 2009. Each record contains 84 demo-
graphic and clinical variables, including most of the pre-
operative features required to validate the BETS models.
Survival was defined as the time elapsed from the date of
surgery to the date of death or last follow-up. The likeli-
hood of survival at 3 and 12 months was the outcome.
This study protocol was approved by the Scandinavian
Sarcoma Group. Informed consent was not required prior
to using de-identified registry data.associates of 12-month survival: surgeon’s estimate of survival,
primary oncologic diagnosis.
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and 10 prognostic features, respectively [4]. These include:
age at the time of surgery (BETS-12 model only), sex, indi-
cation for surgery (impending or completed pathologic
fracture), number of bone metastases (solitary or multiple),
surgeon’s estimate of survival (postoperatively, in months),
presence or absence of visceral metastases, presence or ab-
sence of lymph node metastases, preoperative hemoglobin
concentration (mg/dL, on admission, prior to transfusion,
if applicable), absolute lymphocyte count (K/μL), and the
primary oncologic diagnosis. The oncologic diagnosis was
classified into 3 groups as previously described [4]. Briefly,
breast, prostate, renal cell, and thyroid carcinomas, mul-
tiple myeloma, and malignant lymphoma, which are diag-
noses associated with the longest median survival time,
were included in Group 3; sarcomas and other carcinomas
were included in Group 2; and lung, gastric, and hepatocel-
lular carcinomas and melanoma in Group 1.
The following definitions were used in this study. An
impending pathologic fracture was one in which the degree
of bone and/or cortical disruption warranted prophylactic
surgical stabilization to prevent fracture. A completed
pathologic fracture was one in which the lesion caused a
change in bone length, alignment, rotation, or loss of height
as determined by imaging. Biopsy-proven or clinically obvi-
ous metastases to organs within the chest or abdomen were
considered visceral metastases. Only biopsy-proven metas-
tases to the lymph nodes were considered indicative of
lymph node involvement.
Although missing data are acceptable, the validation
process requires that the specific variables present within
each model also be present within the validation set. To
satisfy this requirement, we converted the Karnofsky per-
formance score, which was recorded in the SSMR, to the
ECOG performance score, which is used by the BETS
models, in a manner described elsewhere [11]. The units
of measure for each variable in the model and validation
sets must also be the same. Therefore, we converted
hemoglobin concentration levels, which were reported in
mmol/L or g/L in the SSMR, to mg/dL using simple
mathematical formulae. No other variables in the valid-
ation set required conversion.Assessment of the BETS models’ performance
The characteristics of the validation set were compared to
those of the test set. Distributions of categorical variables
were compared using the chi-square method, and the
mean values of normally distributed continuous variables
were compared using the Student’s t-test. A two-tailed α
of 0.05 was considered statistically significant. Statistical
analysis was performed using SAS software (version 9.2;
SAS Institute, Inc., Cary, North Carolina, USA), and valid-
ation of the Bayesian models was performed usingcommercially available software (FasterAnalytics, Deci-
sionQ Corp., Washington, DC, USA).
We applied data contained in the validation set to the
BETS-3 and BETS-12 models, which estimated the likeli-
hood of postoperative survival at both 3 and 12 months,
for each record. Receiver-operating characteristic (ROC)
curve analysis was performed, and the area under the
ROC curve (AUC) served as a metric of classifier robust-
ness and accuracy. Validation was considered successful if
the AUC was greater than 0.70 and was determined a
priori. A detailed analysis of incorrect estimations was also
performed.
Results
Eight-hundred and fifteen (815) records contained ad-
equate follow-up information to establish survival at 3 and
12 months postoperatively and thus comprised the va-
lidation set. None of these records were excluded. As
expected, the demographic and clinical features of patients
in the validation set differed from those of patients in the
training set (Tables 1 and 2). Features that differed signifi-
cantly (P < 0.05) were age at surgery, oncologic diagnosis
grouping, presence of visceral and lymph node metastases,
number of bone metastases, pathologic fracture status,
ECOG performance status score, and 12-month mortality.
Nonsignificant differences were observed in sex, preopera-
tive hemoglobin concentration, absolute lymphocyte count,
and 3-month mortality. Most features in the validation set
had varying amounts of missing data. Notable features
included the surgeon’s estimate of survival (not assessed or
recorded in the SSMR database), absolute lymphocyte
count (missing in 84.8%), and lymph node metastases
(missing in 61.7%), all of which are first- or second-degree
associates of survival in both models.
Using a cut point of 0.5, representing a 50% probability
of survival, the BETS-3 model correctly classified
3-month survival in 633 of 815 (77.7%) patients, and the
BETS-12 model correctly classified 12-month survival in
555 of 815 (68.1%) patients. On ROC curve analysis, the
AUCs were 0.79 and 0.76, respectively, for the BETS-3
and BETS-12 models. When compared with the original
cross-validation AUCs of 0.86 and 0.83 [4], this repre-
sents a nontrivial, but acceptable, 0.07-point degradation
in model performance in both the BETS-3 and BETS-12
models.
We analyzed the records that were incorrectly classified
by the BETS-3 (182, 22.4%) and BETS-12 (260, 31.9%), re-
spectively. Of the 182 records incorrectly classified by the
BETS-3 model, 125 (68.7%) were overestimates (patients
did not live as long as expected) and 57 (31.3%) were
underestimates (patients lived longer than expected). How-
ever, the majority (69.6%) of patients in which 3-month
survival was overestimated lived greater than 1 month after
surgery. Of the 260 records incorrectly classified by the
Table 1 Comparison of categorical features between the training and validation sets
Feature Training set (n = 189) Validation set (n = 815) P
No. of patients % No. of patients % % Missing
Sex†‡ male 85 45.0 369 45.3 0 .91
female 104 55.0 446 54.7
Oncologic diagnosis grouping†‡ 1.0 52 27.3 173 21.3 0.4 .001*
2.0 34 18.2 74 9.2
3.0 103 54.5 567 69.1
Visceral metastases†‡ yes 114 60.3 325 39.8 6.1 <.0001*
no 75 39.7 441 54.1
Lymph node metastases†‡ yes 36 18.8 169 20.7 61.8 <.0001*
no 153 81.2 143 17.5
Skeletal metastases†‡ solitary 55 29.0 123 15.1 3.2 <.0001*
multiple 134 71.0 666 81.7
Pathologic fracture status†‡ yes 84 44.2 614 75.3 0.7 <.0001*
no 105 55.8 196 24.0
ECOG performance status†‡ 0,1,2 93 49.2 558 68.5 0 <.0001*
3,4 96 50.8 257 31.5
Survival > 3 months† yes 129 68.3 557 68.3 0 .78
no 60 31.7 258 31.7
Survival > 12 months‡ yes 79 41.8 241 29.6 0 .002*
no 110 58.2 574 70.4
ECOG indicates Eastern Cooperative Oncology Group; % Missing, the proportion of unknown or missing data within the validation set.
*Distributions are significantly different between the training and validation sets by the chi-square· method.
†Denotes feature of 3-month model.
‡Denotes feature of 12-month model.





% Missing data from
validation set
P
Age at surgery (years)‡ Mean 62.4 66.3 0 0.0002*
SD 13.7 12.8
Median 62.7 67.0
IQR 54.4, 72.2 58.0, 76.0
Hemoglobin concentration (mg/dL)†‡ Mean 11.5 11.5 0.6 1.0
SD 1.9 3.5
Median 11.4 11.3
IQR 10.1, 12.9 10.3, 12.6
Absolute lymphocyte count (K/μL)†‡ Mean 1.2 1.2 83.8 0.48
SD 1.3 0.74
Median 1.0 1.2
IQR 0.6, 1.5 0.8, 1.6




SD=standard deviation; IQR=interquartile range; N/A=not applicable.
*Distributions are significantly different between training and validation sets by two-tailed Student’s t-test.
†Denotes feature of 3-month model.
‡Denotes feature of 12-month model.
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http://www.biomedcentral.com/1471-2407/12/493BETS-12 model, 198 (76.2%) were overestimates and 62
(23.8%) were underestimates. Importantly, the majority
(56.5%) of patients in whom 12-month survival was under-
estimated survived less than 2 years after surgery with a
minority (9.6%) surviving longer than 3 years. The overlay
plots (Figures 3 and 4) illustrate which records were cor-
rectly and incorrectly classified as a function of each mod-
el’s estimated probability of survival. In short, incorrect
classifications made by both models tended to be optimis-
tic, overestimating survival in most cases.
Discussion
In this study, we successfully validated two Bayesian mod-
els previously trained to estimate the likelihood of survival
at two time points that are useful for orthopaedic surgical
decision making. Importantly, despite differing patient
populations and varying amounts of missing data, the
BETS-3 and BETS-12 models accurately classified post-op-
erative survival at clinically useful 3- and 12-month time
points.
The models performed well, despite significant differ-
ences between patients in the training and validation sets
(Tables 1 and 2). Scandinavian patients in the validation set
































































Figure 3 Overlay plot of classifications made by the BETS-3 model. Th
incorrectly (red ×) classified as a function of the model’s predicted (estimat
misclassifications were optimistic, with a median estimated probability of 0
survival was overestimated in 142 records (incorrectly classified records from
the estimated 3 months and surgery, performed at the end of life, may hav23.0-96.0; interquartile range, 58.0, 76.0]) than those in the
training set (median age, 62.7 years [total range 20.0-92.0;
interquartile range, 54.4, 72.2]) (P = 0.0002). They were
also nearly twice as likely to be treated for a completed
pathologic fracture, as opposed to undergoing prophylactic
surgery for an impending pathologic fracture (P < 0.0001).
This may explain the significantly lower proportion of
these patients surviving longer than 12 months (P = 0.002).
Nevertheless, there were significantly higher proportions of
Scandinavian patients in the more favorable diagnosis
group (Group 3; P = 0.001) and in the more favorable
ECOG performance status categories (ECOG score 0, 1,
and 2; P < 0.001). However, there was no significant differ-
ence in 3-month survival between patients in the validation
set and those in the test set (P = 0.78). The distributions of
visceral, lymph node, and skeletal metastases also differed
between the two patient populations, but this may be
largely due to the proportion of missing data in the valid-
ation set.
The performance of these models is important, clinic-
ally, because inaccuracies generated by the models are not
of equal significance. For example, BETS-3 was designed
to identify patients that are likely to live at least 3 months
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Figure 4 Overlay plot of classifications made by the BETS-12 model. This plot illustrates which records were correctly (green dot) and
incorrectly (red ×) classified as a function of the model’s predicted (estimated) probability of survival greater than 12 months. Most
misclassifications were optimistic, with a median estimated probability of 0.60 (total range 0.26-0.96; interquartile range 0.51, 0.76). Twelve-month
survival was underestimated in 62 records (incorrectly classified records from probability 0 to 0.5) in which patients lived longer than the
estimated 12 months. They represent cases at risk for implant failure if less-invasive or less durable constructs are used.
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not live at least 3 months, then the surgery may have been
unnecessary. Our data show that 15.3% of records were
misclassified by BETS-3 and survival overestimated, which
translates to 125 potentially unnecessary surgeries per-
formed at the end of life (Figure 3). Of these, 38 (30.4%)
survived less than 1 month, 44 (35.2%) survived between 1
and 2 months and 43 (35.2%) survived between 2 and 3
months. Of course, these data do not distinguish patients
who died of perioperative complications that might have
been independent of the progression of disease, and in
whom surgery was still the best option. Thus, surgery was
still appropriate for many of the patients for whom sur-
vival was overestimated, and 15.3% represents the max-
imum proportion of patients who may otherwise have
been spared surgery in the care of their terminal illness.
In contrast, the BETS-12 model was designed to identify
patients that are expected to live 12 months or longer.
This was done in an effort to help support decisions
regarding the type of procedure required, as well as the
durability of the implant. For example, a surgeon’s deci-
sion to perform a less invasive procedure using a less dur-
able implant such as an intramedullary nail is supported
by a low likelihood of survival at 12 months generated bythe BETS-12 model. If survival is underestimated, and ac-
tual patient survival exceeds 12 months, then the chosen
construct may not have sufficient durability to outlast the
patient. Our results suggest that 7.6% of records may be
underestimated by the BETS-12 model and misclassified
in this fashion. Clinically, this represents a maximum of
62 cases at risk for implant failure that may ultimately
need revision surgery (Figure 4). However, the median sur-
vival for this group of misclassified patients was
18 months [total range 12.0-73.0; interquartile range 13.8,
25.3], with 17 patients surviving longer than 24 months
and only 5 surviving longer than 36 months. As such, rela-
tively few patients, in whom the BETS-12 model underes-
timated survival, may have actually require revision
surgery for implant failure.
Clinicians have long been interested in estimating and
modeling survival in patients with metastatic cancer. For
example, Bauer and Wedin [5] evaluated survival after
orthopaedic stabilization in 241 patients with skeletal me-
tastases. They found that 7 variables were independently
associated with survival. Negatively associated prognostic
variables included pathologic fracture, visceral or brain
metastases, and a diagnosis of lung cancer, whereas posi-
tively associated variables included solitary skeletal
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or kidney carcinoma. Later, after retrospectively analyzing
the records of 460 similar patients, the same group identi-
fied hemoglobin concentration as another negative prog-
nosticator and discriminator of short-term survival [7].
Their work demonstrated that it was possible to make
generalized estimations of survival based on disease-
related and laboratory parameters; however, an accurate,
individualized estimation of survival in this patient popu-
lation was not possible using this method.
In an attempt to generate a prognostic tool useful for
surgical decision-making, Tokuhashi et al. [12] developed a
scoring system by which survival could be categorized into
one of three groups: <6 months, >6 months, or >1 year.
Focusing on only patients with symptomatic spine metas-
tases, the authors collected a series of variables including,
for the first time, Karnofsky performance status [13]. Other
variables included were the number of extra- and intrasp-
inal bone metastases, the number and type (resectable/
nonresectable) of organ metastases, the primary oncologic
diagnosis, and the degree of neurologic impairment. The
group later applied their scoring system to 246 patients
and found that survival greater or less than 6 months could
be reliably estimated using this method [12]. Independent
validation produced similar results [14]; however, this scor-
ing system applies only to patients with symptomatic spine
metastases.
Recognizing the value of a prognostic model that could
be applied to all patients with skeletal metastases, Nathan
et al. [15] evaluated 191 patients undergoing orthopaedic
stabilization for both spine and extremity lesions. In
addition to demographics, disease-specific information,
and performance status [16], Nathan et al. also included a
series of laboratory parameters as candidate variables. A
regression-derived nomogram was developed using eight
independent predictors of survival. This nomogram per-
formed well in a small test set, but, to our knowledge, no
external validation has been attempted.
We chose to use a Bayesian classifier for a variety of rea-
sons. First, we assumed that there are, in the setting of
patients with skeletal metastases, verifiable relationships
between various prognostic features. The Bayesian method
not only generates a joint distribution function describing
the probabilistic relationships between features, but it also
displays it graphically in an intuitive, transparent manner.
This allows the clinician to better understand the hier-
archy, and relative importance, of each feature (Figures 1
and 2) within each model. Second, Bayesian networks can
account effectively for uncertainty within the data, and can
thus be used in the setting of incomplete or missing input
data [17]. This is a significant advantage over the trad-
itional nomogram, when one considers that three of the
first- and second-degree associates of survival—the sur-
geon’s estimate of survival, the absolute lymphocyte count,and the presence of lymph node metastases—were largely
missing from the validation set. More importantly, the
Bayesian method mimics human reasoning by updating
beliefs in response to new evidence [18]. Thus, Bayesian
models can be “improved” from time to time as new evi-
dence becomes available, be it emerging patterns of disease
or more effective treatment modalities. We acknowledge,
however, that additional, prospective data collection is
required to fulfill this goal, and we are committed to this
ongoing investigation.
The BETS models discussed in this paper are clinical de-
cision support models; their output is designed to support
(not replace) good clinical judgment. The goals of surgery
in patients with skeletal metastases are to relieve pain and
to restore function for the maximum amount of time. Be-
cause surgery intended to relieve pain or stabilize patho-
logic fractures is often indicated in patients despite a very
short life expectancy, a low probability of survival gener-
ated by the BETS-3 model should not be used to deny
patients a palliative intervention. On the contrary, if a less
invasive/less durable intervention is planned, low prob-
abilities of survival generated by the BETS-3 and BETS-12
models would support this decision.
This study has several limitations. First, the BETS models
were developed and validated using only patients who
underwent orthopaedic surgery for their skeletal metasta-
ses. Thus, they are not applicable to all patients with meta-
static disease or those in whom skeletal metastases were
treated nonoperatively. Second, the Scandinavian patient
population used for validation was well characterized and
relatively homogeneous, but the generalizability of these
models depends on their performance in a variety of patient
populations with differing institutional biases and treatment
philosophies. Finally, we believe that there is always room
for model improvement, particularly when longer survival
estimates are needed. Additionally, the current models are
relatively optimistic, and additional covariates should be
sought to help identify which patients may die earlier than
expected as well as to better identify patients at risk for
perioperative death. A prospective trial is currently under
way to evaluate new prognostic features that may help esti-
mate the likelihood of individual patient survival at these
and other time points. Finally, the acceptance of clinical
decision-support tools, such as these, depends not only on
validation in additional populations, but also on how the
end-user judges its availability and ease of use. It is difficult,
if not impossible, to represent this classifier on paper so
that other researchers may use it. To address this problem,
we developed an “app” that will make this tool widely avail-
able for such a purpose.
Conclusions
In conclusion, we successfully validated the BETS-3 and
BETS-12 models using an independent, international
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tient. These models represent the first and only validated
tools for accurately estimating postoperative survival in
patients with operable skeletal metastases of the extrem-
ities and can thus provide the surgeon with valuable in-
formation to support clinical decisions.
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